Human mutation · 2026
Integrative Systems Biology and Experimental Validation Unveil GALNT14 as a Novel Diagnostic Biomarker and Therapeutic Target for Sepsis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Xiuqi, Zhai Yi, Yao Jiali, Chen Yue, Ge Wenhan
Аннотация
BACKGROUND: Sepsis lacks reliable biomarkers for early diagnosis and treatment. This study integrates systems biology approaches, weighted gene coexpression network analysis (WGCNA), and experimental validation to identify novel diagnostic and therapeutic targets.
METHODS: Four sepsis-related GEO datasets were analyzed to identify differentially expressed genes (DEGs) and coexpression modules. Machine learning algorithms screened candidate biomarkers from the intersection of DEGs and module hub genes, validated via ROC analysis and immune infiltration assessment. The biological function of the top candidate was verified in vitro using LPS-stimulated THP-1 cells.
RESULTS: GALNT14 was identified as a robust diagnostic biomarker (AUC = 0.79), showing significant correlation with neutrophil and monocyte infiltration. In vitro validation confirmed GALNT14 upregulation in the sepsis model. Functionally, GALNT14 knockdown significantly inhibited proinflammatory cytokines (IL-1β, IL-6, and TNF-α), whereas its overexpression exacerbated the inflammatory response and modulated cell apoptosis.
CONCLUSION: Through a synergistic framework of AI-driven bioinformatics and wet-lab verification, this study identifies GALNT14 as a promising diagnostic biomarker and therapeutic target, mechanistically linking it to the regulation of inflammatory responses in sepsis.
METHODS: Four sepsis-related GEO datasets were analyzed to identify differentially expressed genes (DEGs) and coexpression modules. Machine learning algorithms screened candidate biomarkers from the intersection of DEGs and module hub genes, validated via ROC analysis and immune infiltration assessment. The biological function of the top candidate was verified in vitro using LPS-stimulated THP-1 cells.
RESULTS: GALNT14 was identified as a robust diagnostic biomarker (AUC = 0.79), showing significant correlation with neutrophil and monocyte infiltration. In vitro validation confirmed GALNT14 upregulation in the sepsis model. Functionally, GALNT14 knockdown significantly inhibited proinflammatory cytokines (IL-1β, IL-6, and TNF-α), whereas its overexpression exacerbated the inflammatory response and modulated cell apoptosis.
CONCLUSION: Through a synergistic framework of AI-driven bioinformatics and wet-lab verification, this study identifies GALNT14 as a promising diagnostic biomarker and therapeutic target, mechanistically linking it to the regulation of inflammatory responses in sepsis.